Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How could you have made cash here if the stock price is falling backwards?
Anyone looking at any expert market stocks that are close to becoming pink current and active trading again?
KATX has filed a pre-14C for a 679 to 1 reverse split.
I suppose they need to wait until it is current status before enacting it?
I was just looking at the last posted financials.
They may have decided getting the financials current and being on the hook with the outstanding debt is something they do not want to tackle.
They never updated the financials for this one to become current. Any idea what happened to this one?
Teresa is busy with her tax business.
Maybe AHIX has a new story to tell after April ends and the tax rush is over.
The main people posting negative have been following this company since 2017.
This is not as simple as being sour grapes of buying high and never seeing a positive return.
There is a history of nothing ever being accomplished after positive and promising PRs are released to shareholders.
I believe John's challenge to you is to provide something positive about ENDV as a company and not just having luck on day trading.
If you believe the PRs of future catalysts are a positive....then good luck to you. No forward promises of the past have ever come to fruition with this company.
One needs to really analyze these future catalysts and determine how it will be possible to come true. Watch and see if any of the timelines actually get met.
When will a new update be made on the IHUB APP? I see the last one was June 2023.
I am now experiencing a problem that if I am reading...or worse...writing a message...and someone replies to one of my posts, IHUB closes down. If I was in the middle of a long message, it is lost....grrrrrr.
You might not call it an official 10K anymore, but an annual report is needed by OTC Markets if ENDV wishes to remain "current" status.
See requirements below.
Ongoing Requirements: To qualify for Current Information on an ongoing basis, companies must:
Publish reports through OTCIQ on the following schedule:
Quarterly Report within 45 days of the quarter end
Annual Report within 90 days of the fiscal year end
Attorney Letter within 120 days of the fiscal year end if financial statements are unaudited.
Maintain a Verified Profile. At least once every six months, review and verify the Company Profile through OTCIQ.
Maintain Transfer Agent Verified share data. If your transfer agent participates in the Transfer Agent Verified Shares Program, then your securities must have current share data verified by the transfer agent.
Maintain an Active standing in the Company’s State of Incorporation.
Pink Limited Information Tier
Companies that do not meet the requirements of the Pink Current Information tier set forth above may still qualify for the Pink Limited Information Tier by meeting the following minimum disclosure requirements.
Annual Financial Statements: Publish one set of Qualifying Annual Financial Statements which cover the past 2 completed fiscal years, provided the most recently completed fiscal year is within the past 16 months.
ENDV still has to file 10k to remain compliant with OTC Markets standards.
They are now late.
Let's see how long it takes for Pink Limited status to appear.
Very expensive toilet paper at the moment.
Vince tweeted that sales is strong in January.
Better see some revenue in Q1 ER!!!!
We'll know Vince's interpretation of strong in 1 1/2 months.
Look at this dated website. Has an accusation against Collier for something prior to Endonovo.
https://www.ripoffreport.com/reports/greenbridge-capital-alan-collier-mark-chasan/los-angeles-california-90064/greenbridge-capital-alan-collier-mark-chasan-ppm-deals-are-fraud-ripoff-dishonest-raise-ca-258999
This response is interesting:
"Original poster told the truth. Retraction was not his but written by the accused firm. Check out Alan Collier at Nevada corporations site. He forms new LLCs all the time to cover his tracks and then pretends in California that they are employers when it is all his own LLCs formed with his buddy Garry Kann. Latest one formed on 5/4/09 as Kann Collier & Company. The scam and con has been going for almost 20 years in one form or another. Craig's original post is correct."
I am not the Craig referenced in this post...LOL
Should raise an eyebrow that Gary Kann is affiliated with ENDV and has NO accomplishments since being PR'd exactly 2 years ago. Where are the profitable companies he was acquiring for ENDV portfolio?
The news of concrete and other construction companies are now swept under the rug. No mention of why the promised LOIs never materialized. They expect the shareholders to forget and just keep accepting other fluff PRs.
That response from 2009 appears to still hold water.
10K released.
Just as expected....no revenue from the new business model.
Now we sit in the dark until Q1 release.
Looks like it will be a continued looooong wait.
The investor call did not seem to spark any great excitement.
In 2 weeks, we'll get another peek under the hood when the Q3 ER is released.
8-K released by WORX
Termination of Merger Agreement
On December 22, 2023, SCWorx entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with American Environmental. The material terms of the
proposed merger were disclosed in the Form 8-K filed December 26, 2023.
On March 26, 2024, the parties agreed by mutual consent to terminate the Merger Agreement.
Therefore, the previously proposed merger will not take place, and SCWorx and American Environmental will each continue to operate as separate and independent businesses.
8-K released by WORX
Termination of Merger Agreement
On December 22, 2023, SCWorx entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with American Environmental. The material terms of the
proposed merger were disclosed in the Form 8-K filed December 26, 2023.
On March 26, 2024, the parties agreed by mutual consent to terminate the Merger Agreement.
Therefore, the previously proposed merger will not take place, and SCWorx and American Environmental will each continue to operate as separate and independent businesses.
With the form 15 in effect, Collier can sell his shares without filing form 4 disclosing his stock selling. Let's see how many of the Restricted shares converted in the next share structure update.
GGSM is a non SEC reporting company.
No requirement to file a form 4.
Have you looked at the latest PR for ENDV?
Did you ever invest in the original Reg A?
Check out this website.
https://www.invest-sofpulse.com/
You believe Sofpulse will be able to raise capital and actually make it to NASDAQ?
How can something bought for $4.5M, years ago, with practically no sales, now be worth $50M?
Collier has "intended" to do many things in the past and has never accomplished or followed through with any of them. Just look at every news PR in the past. What has actually ever been accomplished per the past PRs. I can't think of any.
Is now going to be any different?
How many times are people going to allow him to keep moving the goalposts and forgetting/forgiving the empty promises?
This stock is for day trading only. Is certainly not a long term investor hold. Collier has no respect for shareholders or compassion for the $ they lose on this stock. It is all about self enrichment for himself.
Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc
Endonovo Therapeutics, Inc.
Thu, March 28, 2024 at 9:03 AM EDT
Endonovo Therapeutics, Inc.
Los Angeles, CA, March 28, 2024 (GLOBE NEWSWIRE) -- Endonovo (OTC PINK: ENDV) and its subsidiary, SofPulse, Inc., today announced they have finalized and completed the Asset Purchase Agreement (APA), originally signed in December 2023, for the acquisition of Endonovo's assets and Intellectual Property (IP) for a minimum of $50 million.
With completion of the APA, both Endonovo and SofPulse, Inc. share a strategic vision and a commitment for long term growth.
Finalized Terms of SofPulse, Inc. Spin-off
The APA transaction for the purchase of Endonovo assets and IP by SofPulse, Inc. is now closed, pending the customary regulatory approvals.
Key points of the APA include:
Agreement to engage Adeptus, a qualified third party's asset valuation firm.
Acquisition of ENDV IP by SofPulse Inc., including FDA-clearance in the human medical markets, for $50 Million, with potential additional valuation determined by Adeptus (which management believes will be between $50 million to $100 million).
Agreement for SofPulse Inc. to issue $50 million in freely traded stock through an S-1 registration, priced at $5.00 per share to Endonovo.
Register and distribute SofPulse Inc. shares to ENDV's shareholders with its present intention is to distribute 80% of such shares to ENDV shareholders on a date to be determined.
Any additional valuation by Adeptus over $50 million will be paid in cash or in a secured promissory note which will be convertible into NASDAQ listed marketable securities at the sole discretion of the ENDV.
Filing of S-1 registration statement to register the assets being purchased and to fulfill the regulatory requirements for a NASDAQ listing following the sale's completion.
SofPulse, Inc. Capital Raise
SofPulse, Inc. has commenced its capital raise of up to $1,000,000 through a 506(c) -offering tailored for accredited investors. The present capital offering is valued at a pre-money valuation of approximately $25.2 million, with shares priced at $2.50 per share. The capital raise is anticipated to support further development and growth. Upon completion of the capital raise, SofPulse Inc. will look to further develop the assets and IP through additional capital funding rounds to fund its path toward its IPO and NASDAQ registration.
SofPulse Inc. Drives Revenue Growth with Expanded Distribution
SofPulse® Pulsed Electro Magnetic Field (PEMF) medical technology, utilizing its FDA-clearance for the reduction of pain and edema post-operatively, helps to position the Company as a leader in the development of innovative medical devices.
To drive revenue and future expansion, SofPulse, Inc. aims to build on current marketing distribution initiatives for long-term growth and stability in the following areas:
Development of Veterans Association (VA) and Department of Defense (DoD) post-operative pain management market for SofPulse®.
Expand distribution throughout Taiwan, building on Taiwan FDA clearance.
Increase expansion efforts into other Asian markets such as Singapore, South Korea, Thailand, and Hong Kong.
Grow International distribution of SofPulse® in Mexico, Central and South America.
Re-initiate efforts to penetrate European markets with SofPulse® devices.
Expand and develop SofPulse® devices and other new PEMF medical devices for commercialization to all US hospital, surgical and rehabilitation facilities.
Endonovo Market Outlook is Extremely Positive
The Endonovo management team is excited about the completion of the APA and looks forward to the continued growth and success of Endonovo Therapeutics, Inc. through the following areas of business:
Exclusive rights to develop non-medical human PEMF IP and wellness markets.
Development of new non-medical wellness products for the expanding U.S. PEMF therapy device wellness market.
Utilization of groundbreaking multi-coil IP technology for over-the-counter PEMF product development in wellness and human markets.
Maintenance of rights to develop comprehensive telehealth division and platform (SofPulse, Inc. has signed an exclusive agreement to be a customer with a five-year contract).
Continued focus on mergers and acquisitions division to enhance product offerings for new technology and IP.
Endonovo, as business continues to expand, offers additional value to shareholders with the development of the non-medical Wellness market and other opportunities planned by the Company to sustain its long-term growth
SofPulse® PEMF Benefits and Technology Featured in The Press
SofPulse®'s effective non-pharmacological PEMF pain and inflammation management solutions were highlighted in a recent article by Wallstreetpr.com, titled "Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)." The article can be found on MarketScreener, Barchart.com, abnewswire, Benzinga, Muck Rack, The Globe and Mail, and other news outlets.
Click to view article:
https://www.marketscreener.com/quote/stock/PACIRA-BIOSCIENCES-INC-7299436/news/Beyond-the-Pill-Athletes-Champion-PEMF-and-Non-Opioid-Solutions-for-Pain-Management-ENDV-46240551/
About Endonovo Therapeutics, Inc.
Endonovo Therapeutics is currently structured into three divisions- Legacy – a commercial stage developer primarily of medical and non-medical PEMF devices and products; and its Build Up Strategy – acquiring complementary new technology industries; and its Telehealth - focused on bringing Telehealth solutions to the commercial and medical markets. In 2023, Endonovo announced the sale of their medical division and related IP for $50 Million or higher, through an Asset Purchase Agreement (APA) to SofPulse, Inc.. SofPulse Inc., a current subsidiary of Endonovo and a proposed spin-off company through the APA, plans to coordinate the use of SofPulse® and continue to commercialize innovative medical devices globally.
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate", "believe", "plan", "estimate", "expect", "intend" and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date after the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Steve Barnes
sbarnes@endonovo.com
www.endonovo.com
View comments
Please...not a Chinese company.
They are mostly scams...even many on the NASDAQ are.
When are we going to see $2.50?
Seems the brakes have been applied.
What do you think of this?
https://bizfileonline.sos.ca.gov/search/business
Type in Endonovo and you will see they ceased to be a for profit company on 2022 and then in 2023 registered as non-profit???
Saw a comment on Yahoo finance board.
Endonovo is also registered as a company in Delaware. This California change could be insignificant.
Endonovo needs to fire this PR firm.
They are releasing a PR that was initially out in 2016 or sometime close to that year. 😄
Certainly is not applicable to now.
"has plans to apply for orphan drug designation for its next-generation, off-the-shelf treatment of Graft-Versus-Host (GvHD) disease, using enhanced stem cells from the human umbilical cord. If Endonovo receives FDA approval to market its product, the company could easily reach a billion-dollar valuation."
https://blog.doctorsbusinessnetwork.com/biotech-companies-stock-in-your-portfolio/?utm_source=dlvr.it&utm_medium=linkedin
Isn't the device only rated and approved by the FDA for "edema and pain in superficial soft tissue"?
If so, they cannot be reimbursed for "wound" care.
On the Sofpulse investor website, they are still referencing the 2018 valuation report of $75M.
Looks like the updated "true" valuation is never going to happen.
All this volume and the SP can't surpass .0024.
Wonder how many shares are for sale by OTCN?
How are you comparing them?
In what way is it not competition?
Sofpulse has stronger signal. Is marketed for post surgery use and not for every day aches and pains.
They have different application and use.
Using the "preprogrammed" mode, SofPulse
automatically delivers 15 minutes of therapy every two hours, providing at least 8 full days of continuous treatment.
OTC Markets Update
Pink Current, AS: 2.5B, OS: 333M, US: 139M
Officer(s) Added:
🟢Steven Barnes, Vice President
Looks like there was a problem with the form 10.
This was filed 10 days ago.
On February 8, 2024, Tanke Biosciences Inc. (the “Company”) initially filed Registration Statement No. 000-53529 on Form 10-12G (together with the exhibits thereto, the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”).
The Company hereby requests that the Commission consent to the withdrawal of the Registration Statement effective as of the date hereof. The Company is seeking withdrawal of the Registration Statement because the Auditor who completed the 2022 audit is no longer registered with the PCAOB. The Registration Statement has not been declared effective by the Commission and no securities have been issued or sold under the Registration Statement. Based on the foregoing, the Company submits that the withdrawal of the Registration Statement is consistent with the public interest and the protection of investors.
It is "rated" for 100+ treatments with the pre-programmed continuous auto cycle and 150+ with the manual use of it.
These are the official numbers released by the company but can go longer depending upon the quality of the battery.
Wrong stock board.
USCS is still on Expert Market.
They are not current on releasing the financials
When you go to the website....at the very bottom of the main page, it has the year 2020.
Wouldn't that date/year change when there is an actual update to the website?
They could use some help in creating a better site. They could market themselves better by mentioning all the patents they have with their technology. I see no mention of them.
ADM Tronics to Host Shareholder Video Call on March 27 to Update Launch and Significance of Vet-Sonotron Veterinary Pain Treatment Device
NORTHVALE, NJ / ACCESSWIRE / March 20, 2024 / ADM Tronics (OTCQB:ADMT), an innovator of electronic medical device technologies, invites shareholders to a shareholder video call on March 27, 2024 at 2 PM Eastern, where shareholders will be updated about ADMT's new proprietary Vet-Sonotron®, non-invasive veterinary therapeutic technology. The Vet-Sonotron has demonstrated positive efficacy in treating pain and inflammation, without drugs nor adverse side effects, and is now in initial commercialization for pets and other animals, including horses.
Based on the positive therapeutic results demonstrated by the Vet-Sonotron, ADMT is in development of a human medical version - the Sonotron. When development is completed, ADMT intends to submit a 510(k) to the FDA for the Sonotron for use in the treatment of chronic and acute musculoskeletal pain conditions in humans. The non-invasive therapy delivered by the Sonotron has no known side effects and may be an effective option to pain drugs that have potential negative side effects and dependencies. Management believes the Sonotron technology has the potential to impact shareholder valuations significantly should FDA clearance be secured.
The shareholder video call will be held March 27, 2024 at 2:00 PM Eastern Daylight Time.
Register in advance for this meeting:
https://us06web.zoom.us/meeting/register/tZcsd-qgqjguG93zMFc_rH4IEpdDYQ2NWjEl
After registering, you will receive a confirmation email containing information about joining the meeting.
For more information about the Vet-Sonotron visit www.vet-sonotron.com.
ADMT welcomes inquiries for its medical device contract engineering and manufacturing services at www.admteng.com.
About ADMT
ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Engineering, Regulatory and Manufacturing Services; and, Eco-Friendly, Water-Based Formulations. The Company's headquarters, laboratories, and FDA-Registered medical device manufacturing operations are in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, for research, development and commercialization of diversified technologies. Visit www.admtronics.com.
Sonotron® is a registered trademark of ADM Tronics Unlimited, Inc.
Investor Relations:
Howard Isaacs 562-987-4939 HISAACS@EARTHLINK.NET
Richard Cavalli 303-956-1777 RICHARDACAVALLI@GMAIL.COM
You doing Jeep week in Moab next week?
Hells Revenge Trail!!!
Can understand why you could not wait any longer if that's the case. Timing was just bad for you.
Yeah....this has happened several times over the years. Some mysterious trading going on behind the scenes. This would be a good case study for the SEC.
There is still a lot of convertible debt on the books and new convertible debt being initiated to this day.
I thought they PRd no more convertible loans moving forward but yet in December, they created new debt with future conversions.